|Table of Contents|

Oleandrin induces immunogenic cell death of liver cancer cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1787-1791
Research Field:
Publishing date:

Info

Title:
Oleandrin induces immunogenic cell death of liver cancer cells
Author(s):
SU Nan; GAO Xiaoxin; CHEN Shi; LIAO Yiming; ZHANG Guirong
Central Laboratory,Liaoning Cancer Hospital ＆ Institute,China Medical University Cancer Hospital,Liaoning Shenyang 110042,China.
Keywords:
Oleandrin; liver cancer; immunogenic cell death; immunotherapy
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.10.004
Abstract:
Objective：To investigate the underlying mechanism of Oleandrin inducing immunogenic cell death of liver cancer cells.Methods:Human liver cancer cells HuH-7 and HepG2 were cultured in vitro.A control group and an Oleandrin group were set up.The cell viability was detected by CCK8.The contents of high mobility group box 1 (HMGB1) and adenosine triphosphate (ATP) in the cell supernatant were detected by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence,respectively.The extramembrane translocation of cellular calreticulin (CRT) was detected by immunofluorescence and flow cytometry.The protein expression and phosphorylation changes of PERK and eIF2α in the endoplasmic reticulum stress signaling pathway were detected by Western blot.Results:After Oleandrin affecting on the liver cancer cells HuH-7 and HepG2,the cell viability decreased significantly.Oleandrin could induce immunogenic cell death in liver cancer cells,cause the release of ATP and HMGB1 and the membrane translocation of CRT in liver cancer cells,and at the same time increase the expression level of proteins related to the endoplasmic reticulum stress signaling pathway (p-PERK,eIF2α and p-eIF2α,etc.).Conclusion:Oleandrin may induce immunogenic cell death in liver cancer cells by activating endoplasmic reticulum stress signaling pathway.

References:

［1］ VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma［J］.Lancet,2022,400(10360):1345-1362.
［2］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［3］ SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
［4］ CHAKRABORTY E,SARKAR D.Emerging therapies for hepatocellular carcinoma (HCC)［J］.Cancers (Basel),2022,14(11):2798.
［5］ YARCHOAN M,AGARWAL P,VILLANUEVA A,et al.Recent developments and therapeutic strategies against hepatocellular carcinoma［J］.Cancer Res,2019,79(17):4326-4330.
［6］ MEDAVARAM S,ZHANG Y.Emerging therapies in advanced hepatocellular carcinoma［J］.Exp Hematol Oncol,2018,7:17.
［7］ KO YS,RUGIRA T,JIN H,et al.Oleandrin and its derivative odoroside A,both cardiac glycosides,exhibit anticancer effects by inhibiting invasion via suppressing the STAT-3 signaling pathway［J］.Int J Mol Sci,2018,19(11):3350.
［8］ PAN L,ZHANG Y,ZHAO W,et al.The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway［J］.Cancer Chemother Pharmacol,2017,80(1):91-100.
［9］KANWAL N,RASUL A,HUSSAIN G,et al.Oleandrin:A bioactive phytochemical and potential cancer killer via multiple cellular signaling pathways［J］.Food Chem Toxicol,2020,143:111570.
［10］ MIJATOVIC T,VAN QUAQUEBEKE E,DELEST B,et al.Cardiotonic steroids on the road to anti-cancer therapy［J］.Biochim Biophys Acta,2007,1776(1):32-57.
［11］ PRASSAS I,DIAMANDIS EP.Novel therapeutic applications of cardiac glycosides［J］.Nat Rev Drug Discov,2008,7(11):926-935.
［12］ LI X,ZHENG J,CHEN S,et al.Oleandrin,a cardiac glycoside,induces immunogenic cell death via the PERK/eIF2α/ATF4/CHOP pathway in breast cancer［J］.Cell Death Dis,2021,12(4):314.
［13］ LLOVET JM,ZUCMAN-ROSSI J,PIKARSKY E,et al.Hepatocellular carcinoma［J］.Nat Rev Dis Primers,2016,2:16018.
［14］ XU J,WAN Z,TANG M,et al.N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling［J］.Mol Cancer,2020,19(1):163.
［15］ WANG H,LIU Y,XU M,et al.Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma［J］.Biomater Sci,2019,7(10):4166-4173.
［16］ SANTOS PM,BUTTERFIELD LH.Next steps for immune checkpoints in hepatocellular carcinoma［J］.Gastroenterology,2018,155(6):1684-1686.
［17］ SANGRO B,SAROBE P,HERVS-STUBBS S,et al.Advances in immunotherapy for hepatocellular carcinoma［J］.Nat Rev Gastroenterol Hepatol,2021,18(8):525-543.
［18］ YU Z,GUO J,HU M,et al.Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma［J］.ACS Nano,2020,14(4):4816-4828.
［19］ KROEMER G,GALLUZZI L,KEPP O,et al.Immunogenic cell death in cancer therapy［J］.Annu Rev Immunol,2013,31:51-72.
［20］ FRIDMAN WH,ZITVOGEL L,SAUTS-FRIDMAN C,et al.The immune contexture in cancer prognosis and treatment［J］.Nat Rev Clin Oncol,2017,14(12):717-734.

Memo

Memo:
-
Last Update: 1900-01-01